Glycogen storage disease type Ib (GSD-Ib) is caused by mutations of the glucose-6-phosphate transporter (G6PT) and characterized by disrupted glucose homeostasis, neutropenia, and neutrophil dysfunction. To investigate the role of G6PT in human adipose-derived mesenchymal stem cells (hMSCs), the G6PT gene was mutated by CRISPR/Cas9 technology and single cell-derived G6PT À/À hMSCs were established. G6PT À/À hMSCs have significantly increased cell proliferation but impaired adipogenesis and osteogenesis. These phenotypes are associated with two mechanisms: i) metabolic reprogramming in G6PT À/À hMSCs causing a metabolic shift toward glycolysis rather than oxidative phosphorylation and ii) increased cyclooxygenase-2-derived prostaglandin E 2 secretion in G6PT À/À hMSCs. This study demonstrates that G6PT is essential for proliferation and differentiation of MSCs, providing important insights into the GSD-Ib phenotypes.
Mesenchymal stem cells (MSCs) are adult multipotent stem cells that can be isolated from several tissues including bone marrow and adipose tissue [1, 2] . MSCs have the capability of self-renewal and differentiation into multiple cell lineages such as adipocytes, osteocytes, and chondrocytes, and they have been reported to transdifferentiate into other lineages such as neurons, glial cells, endothelial cells, and hepatocytes [3] .
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This differentiation capability makes MSCs a promising source for cell therapy in regenerative medicine [4] . In addition to their potential for ex vivo expansion and differentiation, MSCs have been found to have immunosuppressive activities, making MSCs potential candidates for the treatment of immune disorders such as sclerosis, rheumatoid arthritis, and inflammatory bowel disease [2] . The glucose-6-phosphate transporter (G6PT) is a ubiquitously expressed protein localized in endoplasmic reticulum (ER) membrane [5] . The primary role of G6PT is to transport G6P from the cytoplasm into the lumen of the ER, where it is hydrolyzed into glucose and phosphate by glucose-6-phosphatase-a or glucose-6-phosphatase-b (G6Pase-a or G6Pase-b) [5, 6] . Deficiencies of G6Pase-a, expressed primarily in the liver, kidney, and intestine, and ubiquitous expression of G6Pase-b cause glycogen storage disease type Ia (GSD-Ia) and severe congenital neutropenia syndrome type 4 (SCN4), respectively [6, 7] . In contrast, G6PT deficiency causes GSD type Ib (GSD-Ib), manifesting not only disturbed glucose homeostasis similar to GSD-Ia, but also immune deficiency due to neutropenia and neutrophil dysfunction [8, 9] . It has been described that loss of G6PT activity in GSD-Ib causes ER and oxidative stress and accelerated apoptosis, leading to neutropenia [10] and impaired energy homeostasis, characterized by underlying neutrophil dysfunction such as impairment in respiratory burst, chemotaxis, and calcium mobilization [9] . Recently, it was also reported that G6PT deficiency affects engagement of glycolysis by T cells and results in impaired functionality of regulatory T cells, suggestive of increased autoimmunity risk in GSD-Ib [11] . In parallel with ubiquitous expression of G6PT, it is therefore reasonable to suggest that G6PT is essential for functioning of different cells.
In this study, we hypothesized that loss of G6PT activity could alter the metabolism of MSCs, consequently affecting their proliferation and differentiation. To provide an insight into the function of G6PT in MSCs, we created G6PT knockout adipose-derived MSCs using the CRISPR/Cas9 system, and tested proliferation as well as the ability of G6PT À/À cells to differentiate into adipocytes and osteoblasts in vitro. We noted increased proliferation and impaired adipogenic and osteogenic differentiation. These phenotypes are in part associated with a shift toward glycolysis and stress-dependent Cox-2-derived PGE 2 secretion. Therefore, we suggest that G6PT plays a critical role in the proliferation and differentiation of MSCs via regulation of their metabolism.
Materials and methods

Cell culture
Adipose-derived hMSCs (American Type Culture Collection; ATCC-SCRC-4000, Manassa, VA, USA) were used throughout this study. Cells were cultured and maintained in MesenPro RS medium (Thermo Scientific, Waltham, MA, USA) supplemented with G418 (LPS Solution, Daejeon, Korea) at a concentration of 0.2 mgÁmL À1 at 37°C in an atmosphere of 5% CO 2 . The medium was changed every other day until the cells reached 80% confluence prior to passaging.
Establishment of Cas9-mediated G6PT À/À hMSC For knockout of the human G6PT gene in hMSCs, Cas9 endonuclease target loci were designed in exon 1 of the human G6PT gene (Fig. 1A) . Two gRNAs were designed with each 19 bp target sequence followed by protospacer adjacent motif (PAM) sequences (Fig. 1A) . Co-transfection, sorting, genotyping, and sequencing were performed as described previously [12] . Potential off-target sites were identified using TagScan (http://www.isrec.isb-sib.ch/tagge r), a web tool providing genome searches for short sequences, followed by PCR and sequencing.
Immunophenotyping MSC phenotype was evaluated by the expression of CD29-PE, CD90-PE, CD105-PE, and CD44-FITC (BD Biosciences, Franklin Lakes, NJ, USA). Cells at passages 3 and 25 were incubated for 30 min at 4°C in the dark with antibodies and flow cytometry was performed on a Guava EasyCyte (Millipore, Burlington, MA, USA). The data were analyzed using FlowJo v7.0 (TreeStar).
Cell growth and cell cycle analysis
To compare the cell growth of G6PT À/À and control hMSCs, cells (2 9 10 4 ) were plated in a 6-well plate and cultured for 4 days. Cells were trypsinized daily and counted using a hemocytometer. For cell cycle analysis, cells were seeded into 100 mm plates at 5 9 10 3 cellsÁcm
À2
. After 48 h, cells were fixed in 1 mL icecold 70% ethanol for 1 h at À20°C. Once fixed, cells were washed in PBS and then stained with propidium iodide (PI; 0.05 mgÁmL
À1
) staining solution containing 10 mgÁmL
RNase A (Navigen, Salt Lake City, UT, USA) for 30 min at 37°C in the dark. Cell cycle distribution was determined using a Guava EasyCyte and analysis was performed with FlowJo v7.0.
Adipogenic and osteogenic differentiation of hMSCs
To induce differentiation of hMSCs into adipocytes and osteoblasts, 4.75 9 10 4 cells were seeded in 6-well plates. When the cells reached approximately 80% and 60% confluency for adipogenic and osteogenic differentiation, respectively, the medium was replaced with StemPro Adipogenesis and Osteogenesis Differentiation Kit Medium (Thermo Scientific); the differentiation media were changed every 3 days. At day 13 after adipogenic induction, cells were fixed with 10% formalin for 1 h. After washing with 60% isopropanol, cells were stained with Oil Red O staining solution (Sigma-Aldrich, St. Louis, MO, USA) for 10 min at room temperature, followed by four consecutive washes with distilled water. At day 17 after osteogenic induction, cells were fixed with 10% formalin for 1 h, followed by two consecutive washes with distilled water. The cells were then stained with alkaline phosphatase (ALP; Sigma-Aldrich) for 15 min at room temperature and washed with PBS. Images were acquired using a light microscope (Olympus, Shinjuku, Japan). ImageJ software v1.50 (National Institutes of Health) was used to analyze the quantity of the positively stained areas.
Western blot and quantitative real-time reversetranscription-polymerase chain reaction (RT-PCR) analysis
Western blot analysis was conducted as described previously [9] . Mouse monoclonals used were KDEL (Stressgen, Farmingdale, NY, USA), cyclin D1 (Santa Cruz Biotechnology, Dallas, TX, USA), and hexokinase 2 (HK2, Abcam, Cambridge, UK). Rabbit polyclonals used were superoxide dismutase-2 (Sod-2; Millipore), total and phosphorylated glycogen synthase kinase-beta (GSK-3b and pGSK-3b; Cell Signaling, Danvers, MA, USA), total and phosphorylated Akt (Cell Signaling). Goat polyclonal used was cyclooxygenase-2 (Cox-2; Santa Cruz Biotechnology). Protein expression was then quantified by densitometry analysis with ImageJ v1.50. Total RNA was extracted from hMSCs using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA). Expression of mRNA was quantified by real-time RT-PCR using an AriaMx Real-Time PCR System (Agilent Technologies, Santa Clara, CA, USA). The sequences for each primer pair are shown in Table S1 .
Measurement of cytosolic reactive oxygen species (ROS) and PGE 2
Intracellular levels of ROS were assessed as described previously [13] To determine the secretion level of PGE 2 , culture supernatants were collected from cells cultured in 6-well plates for 2 days. To determine PGE 2 concentration, a commercial ELISA kit for PGE 2 (Cayman Chemical, Ann Arbor, MI, USA) was used according to the manufacturer's protocol.
Statistical analysis
Data are presented as the mean AE standard deviation and were assessed by the Student's t-test with GraphPad Prism 5. Values were considered statistically significant at P < 0.05.
Results
Establishment and characterization of G6PT
À/À hMSCs The target gRNA sites were designed against the human G6PT gene (Fig. 1A) . After co-transfection of the Cas9 and G6PT gRNA expression vectors into hMSCs, GFPpositive cells were identified by FACS, followed by in vitro expansion of a single cell. The CRISPR/Cas9-mediated knockout genotype was validated by sequencing (Fig. 1A) . The expression level of G6PT was decreased to approximately 36% in G6PT À/À hMSCs compared with that of control hMSCs (Fig. 1B) . The expression of G6Pase-b and G6PT isotypes such as SLC37A1, SLC37A2, and SLC37A3 was not shown to be altered in the deficiency of G6PT (data not shown).
To exclude potential off-target effect, we identified four putative off-target sites (Table S2 ) and conducted PCR to amplify and sequence the genome regions with predicted potential off-targets. No mutations were detected in any of the sites for G6PT À/À hMSCs (Fig. S1 ). Morphology of G6PT À/À hMSCs was not different from that of the control hMSCs which was supported by no significant change in either size (forward scatter) or granularity (side scatter) (Fig. 1C) . Furthermore, it was found that the expression of MSC markers on G6PT À/À MSCs, such as CD29, CD44, CD90, and CD105, was similar to that of control MSCs both at passages P3 and P25 (Fig. 1D) .
Deficiency of G6PT increases proliferation of hMSCs via an increase in S and G2/M populations and a decrease in G1 populations
To assess the proliferative activity of G6PT À/À MSCs, (D) Measurement of cyclin D1 expression levels and quantification by Western blotting. *P < 0.05, ** P < 0.01.
indicated time points ( Fig. 2A,B) . The proliferation of G6PT À/À MSCs was significantly increased compared with that of the control. In parallel with increased cell growth, cell cycle analysis by flow cytometry showed that G6PT À/À MSCs had a reduction in the fraction of cells in G0/G1 phases (75.20 AE 0.37% vs. 71.10 AE 1.01%) with a concomitant increase in the fraction of cells in S (6.00 AE 0.60% vs. 7.59 AE 0.33%) and G2/M (18.80 AE 0.67% vs. 21.31 AE 0.74%) phases compared with control MSCs (Fig. 1C) . Consistent with this, the expression of cyclin D1 was found to be higher in G6PT À/À MSCs compared with control MSCs (Fig. 1D) .
Reduced adipogenic and osteogenic differentiation of G6PT À/À MSCs
To study the effect of G6PT deficiency on the pluripotency of hMSCs, we examined the differentiation potential of G6PT À/À MSCs into adipocytes and osteoblasts.
The positive area of oil red O staining for lipid droplets was much lower in G6PT À/À MSCs than that in control MSCs (Fig. 3A) . Consistently, the expression levels of peroxisome proliferator-activated receptor gamma (PPARc), fatty acid-binding protein 4 (FABP4), and adiponectin were significantly lower in G6PT À/À MSCs than in control MSCs (Fig. 3B) . For osteogenesis, the positive area of ALP staining was lower in G6PT À/À MSCs than in control MSCs (Fig. 3C) , and markers of osteogenic differentiation (RUNX2, osteocalcin, and PPARc) were downregulated in G6PT À/À MSCs (Fig. 3D) . The results indicate that G6PT deficiency significantly inhibits the ability of MSCs to differentiate into adipocytes and osteoblasts.
Differential expression of hexokinase 2 and uncoupling protein 2 in G6PT À/À MSCs
To investigate the molecular mechanisms governing increased proliferation and impaired differentiation in 
G6PT
À/À MSCs, we examined the expression levels of key glycolytic enzymes hexokinases (HKs) such as HK1 and HK2 and mitochondrial uncoupling proteins (UCPs). As shown in Fig. 4A and B, HK2 was upregulated in G6PT À/À MSCs at both mRNA and protein levels with no change in HK1. HK2 is known to be regulated by the Akt signaling pathway, which is implicated in glucose metabolism and cell survival in many types of cells via phosphorylation of Akt and GSK-3b [14] . As shown in Fig. 4C , phosphorylation at Ser473 of Akt and Ser9 of GSK-3b was highly induced in G6PT À/À MSCs. In contrast, a mitochondrial carrier, UCP2, whose expression is also involved in cell proliferation [15] , was significantly reduced in G6PT À/À MSCs, but this was not observed for other UCPs (Fig. 4D) . Altogether, these results suggest that the genetic loss of G6PT induces a metabolic shift toward glycolysis rather than oxidative phosphorylation.
ER and mitochondrial oxidative stress in G6PT
À/À
MSCs
We assessed the effects of G6PT deficiency on ER and oxidative stress based on our previous finding that G6PT deficiency induces unfolded protein responses and mitochondrial oxidative stress in neutrophils [10] . Western blot analysis showed that expression of GRP78 and Sod-2 was upregulated in G6PT À/À MSCs, indicating ER and mitochondrial oxidative stress, respectively (Fig. 5A) . To support the effect on mitochondrial oxidative stress, we examined the intracellular ROS levels in MSCs, consequently indicating that (F) mRNA levels of EP receptors. Data represent the mean AE SEM (n = 3). *P < 0.05, **P < 0.01. Fig. 6 . Graphical summary depicting the effects of G6PT deficiency on metabolism of MSCs, affecting their proliferation and differentiation. G6PT deficiency causes increased cell proliferation but impaired adipogenic and osteogenic differentiation compared with control MSCs. These phenotypes can be explained by two proposed mechanisms: i) metabolic reprogramming in G6PT À/À hMSCs causing a shift toward glycolysis, which is associated with upregulation of hexokinase 2, phosphorylation of Akt and glycogen synthase kinase-b, and reduced uncoupling protein 2 expression, and ii) stressdependent cyclooxygenase-2-derived prostaglandin E 2 secretion in G6PT
production compared with that of control MSCs (Fig. 5B) .
Upregulation of Cox-2, PGE 2 , and E-Prostanoid receptors in G6PT À/À MSCs Cox-2, which controls PGE 2 synthesis as a rate-limiting enzyme, has been reported to be induced by ER stress and is involved in regulating cell proliferation [16] [17] [18] . Therefore, we examined the expression of Cox-2 and verified the levels of PGE 2 production. The expression of Cox-2 was significantly higher in G6PT
MSCs than that of control MSCs at both mRNA and protein levels (Fig. 5C,D) . (Fig. 5E ). PGE 2 plays a regulatory role in hMSC proliferation and this regulation is known to involve E-Prostanoid (EP) receptors [16, 19] . Therefore, we assessed the expression of EP receptors in control and G6PT À/À MSCs. As shown in Fig. 4F , both control and G6PT À/À MSCs expressed four EP receptor subtypes, and expression was shown to be much higher in G6PT À/À MSCs than in control MSCs.
Discussion
GSD-Ib is a rare inherited metabolic disorder caused by a deficiency in G6PT, which is ubiquitously expressed and plays a role in the transfer of cytoplasmic G6P into the lumen of the ER [8] . Consequently, GSD-Ib is impaired in gluconeogenesis and glycogenolysis, resulting in hypoglycemia, hepatomegaly, nephromegaly, and an abnormal metabolic profile [20] . GSD-Ib also manifests as neutropenia and neutrophil dysfunction resulting in recurrent bacterial infections [8] . Previously, we reported that neutropenia in GSD-Ib is caused by enhanced neutrophil ER stress and apoptosis [10] . Moreover, impaired neutrophil energy homeostasis and activation of hypoxia-inducible factor-1a(HIF-1a)/peroxisome-proliferators-activated receptor-c (PPARc) signaling are implicated in part in neutrophil dysfunction in GSD-Ib [9] . Most recently, Melis et al. [11] showed lymphopenia and a reduced suppressive activity of regulatory T cells in GSD-Ib, which underlies an increased autoimmune risk.
In the present study, we knocked out the human G6PT gene in adipose-derived MSCs and isolated a single cell-derived subline using the CRISPR/Cas9 system and FACS. We found that MSCs deficient in G6PT expression exhibit a higher growth rate than control cells and impaired adipogenic and osteogenic differentiation. This aberrant proliferation and differentiation of G6PT À/À MSCs can be in part attributed to increased glycolysis and Cox-2-mediated PGE 2 .
These results indicate that G6PT plays a critical role in regulating MSC activity including proliferation and differentiation (Fig. 6) . Examination of the G6PT À/À hMSC morphology and immunophenotype revealed that there is no significant difference between G6PT À/À and control hMSCs. However, the loss of G6PT activity resulted in increased proliferation and impaired differentiation of adipose-derived hMSCs. The reasons for these results may be associated with altered metabolism of G6PT À/À hMSCs, that is, a metabolic shift toward glycolysis rather than oxidative phosphorylation, in part supported by differential expression of the glycolytic enzyme HK2 and the mitochondrial anion carrier UCP2. HK catalyzes the phosphorylation of glucose which is the rate-limiting first step of glycolysis. HK2 is a predominant isoform in proliferating cells and its upregulation has been known to be a major contributor to the elevated glycolysis observed in many types of tumor cells [14] . In contrast, UCP2 expression level correlates negatively with proliferation of cancer cells [21] , which also involves metabolic reprogramming, i.e., decreased glycolysis and increased oxidative phosphorylation in cancer cells overexpressing UCP2 [21] . This altered metabolism may inhibit adipogenic and osteogenic differentiation of G6PT À/À MSCs, since a metabolic switch from glycolysis to oxidative phosphorylation has been known to occur during adipogenic and osteogenic differentiation of MSCs derived from bone marrow and adipose tissues [22, 23] . The exact mechanisms of how G6PT deficiency increases HK2 expression remain unclear; however, HK3, a major HK isozyme in neutrophils, has been previously shown to be upregulated in neutrophils of GSD-Ib patients caused by activation of the HIF-1a/ PPARc pathway [9] . In the present study, Akt and GSK-3b, one of the most established downstream effectors of Akt, were shown to be highly phosphorylated at Ser473 and Ser9, respectively, in G6PT À/À MSCs, indicating the activation of Akt signaling which in turn may lead to activation of HIF-1a, although further study is required.
Another possible explanation for the aberrant proliferation and differentiation is the induction of Cox-2 and PGE 2 in G6PT À/À MSCs (Fig. 5) . Cox-2, a ratelimiting enzyme for prostaglandin (PG) synthesis, is an inducible isoform which is rapidly expressed in several cell types in response to pro-inflammatory cytokines, tumor promoters, oncogenes, and growth factors [24] . Cox-2 induction is associated with an increased production of PGE 2 which is known to modulate cell proliferation and differentiation [16, 17, 25] . Furthermore, the effect of PGE 2 on cell proliferation has been reported to be regulated via GSK-3b phosphorylation at Ser9 and in turn, the inhibition of GSK-3b activity by phosphorylation at Ser9 upregulates the expression of cyclin D1 [16] . In this study, we found that the phosphorylation at Ser9 of GSK-3b was significantly increased in G6PT À/À MSCs, suggesting that increased Cox-2 expression, PGE 2 secretion, and phosphorylation of GSK-3b may be involved in aberrant proliferation and differentiation of G6PT À/À MSCs. The exact mechanism of upregulation of Cox-2 expression needs to be investigated, but one possible explanation is that ER and oxidative stresses may induce the expression of Cox-2 [18, 26] . Here, we showed that GRP78 as a ER stress marker and Sod-2 and ROS as oxidative stress markers were increased in G6PT-deificient MSCs.
In conclusion, to the best of our knowledge, this is the first report showing that G6PT is essential for proliferation and adipogenic and osteogenic differentiation of MSCs. Ultimately, this model could be instrumental in the study of how MSCs regulate their proliferation and differentiation and could be essential in understanding the pathogenesis implicated in GSD-Ib.
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